AGAT Deficiency

Key Findings

Finding 1: AGAT Deficiency is a Rare Autosomal Recessive Creatine Biosynthesis Disorder Caused by Biallelic GATM Mutations

AGAT deficiency is the rarest of the three cerebral creatine deficiency syndromes (CCDS). The GATM gene (HGNC:4175, NCBI Gene 2628, Ensembl ENSG00000171766) on chromosome 15q21.1 encodes the mitochondrial enzyme L-arginine:glycine amidinotransferase. In the largest published cohort, 16 patients from 8 families of 8 different ethnic backgrounds were characterized (PMID: 26490222). The ClinGen Creatine Deficiency Syndromes Variant Curation Expert Panel (CCDS VCEP) has curated 45 variants in GATM to date (PMID: 38452609). Key identifiers include OMIM 612718, Orphanet 35704, and MONDO:0012999. As stated by Stockler-Ipsiroglu et al.: "Arginine:glycine aminotransferase (AGAT) (GATM) deficiency is an autosomal recessive inborn error of creative synthesis" (PMID: 26490222).

Finding 2: Clinical Phenotype — Intellectual Disability, Language Impairment, Myopathy, Behavioral Disturbances, and Epilepsy

In the cohort of 16 patients, 15/16 (94%) had intellectual disability or developmental delay, and 8/16 (50%) had myopathy or proximal muscle weakness (PMID: 26490222). Common features include severe language impairment and behavioral disorders. Recently, the phenotype has been expanded to include epilepsy: "This study presents the first reported epilepsy cases in AGAT deficiency" (PMID: 40674085). Detailed characterization revealed that "Two individuals had focal epilepsy with sensory seizures characterized by a prominent 'tingling' sensation. Three experienced febrile seizures plus and marked temperature sensitivity. Corpus callosum dysmorphisms were observed in three cases" (PMID: 40323733). Cortical thickness was significantly reduced across multiple brain regions despite creatine supplementation.

Finding 3: Creatine Supplementation is Effective, Especially When Started Early

Oral creatine monohydrate at 100–800 mg/kg/day results in almost complete restoration of brain creatine levels (PMID: 26490222). Two patients treated since ages 4 and 16 months had normal cognitive and behavioral development at ages 10–11 years. In one patient treated from 16 months, "8 years post initiation of oral creatine supplementation, patient demonstrates superior nonverbal and academic abilities, with average verbal skills" (PMID: 22386973). Late-treated patients showed limited cognitive improvement but significant myopathy improvement. The 15-year follow-up confirmed that "Cr treatment is considered safe and well tolerated but side effects, including weight gain and kidney stones, have been reported. Early treatment prevents adverse developmental outcome" (PMID: 28148286).

Finding 4: Distinctive Biochemical Signature Enables Differential Diagnosis

Low/undetectable GAA and low creatine in body fluids, combined with absent brain creatine on MRS, form the pathognomonic biochemical profile. As reported: "Common biochemical denominators were low/undetectable guanidinoacetate (GAA) concentrations in urine and plasma, and low/undetectable cerebral creatine levels" (PMID: 26490222). This distinguishes AGAT deficiency from GAMT deficiency (elevated GAA, low creatine) and creatine transporter deficiency (elevated urine creatine/creatinine ratio): "low guanidinoacetate and low creatine levels in body fluids in l-arginine:glycine amidinotransferase deficiency, and elevated creatine-to-creatinine ratio in urine in creatine transporter deficiency" (PMID: 36856349).

Finding 5: Mouse Model Reveals Cardiac and Muscle Vulnerability

AGAT-knockout mice exhibit reduced cardiac contractility with significantly lower L-type calcium channel current amplitude, slower inactivation, and slower calcium transient decay, rescued by creatine supplementation (PMID: 33275525). Additionally, "Simvastatin-induced motor impairment was exacerbated in AGAT-deficient mice compared with AGAT-overexpressing GAMT" deficient mice (PMID: 31853708). The GATM gene was associated with statin-induced myopathy in two human populations, suggesting translational relevance.

1. Disease Information

Overview

AGAT deficiency (also known as GATM deficiency, arginine:glycine amidinotransferase deficiency, or cerebral creatine deficiency syndrome 3) is the rarest of the three cerebral creatine deficiency syndromes (CCDS). It results from complete or near-complete loss of AGAT enzymatic activity, preventing the first step in endogenous creatine biosynthesis. The disease was first described in the early 2000s, following earlier discoveries of GAMT deficiency (1994) and creatine transporter deficiency (2001).

Key Identifiers

Synonyms and Alternative Names

• Arginine:glycine amidinotransferase deficiency (AGAT-d)
• GATM deficiency
• Cerebral creatine deficiency syndrome 3 (CCDS3)
• L-arginine:glycine amidinotransferase deficiency
• Creatine deficiency syndrome due to AGAT deficiency
• Glycine amidinotransferase deficiency

Information Source

This report is derived from aggregated disease-level resources (OMIM, Orphanet, PubMed literature, ClinVar, ClinGen) and individual patient-level case reports/case series. The largest single cohort study characterized 16 patients from 8 families (PMID: 26490222).

2. Etiology

Disease Causal Factors

AGAT deficiency is exclusively genetic in origin. It is caused by biallelic (homozygous or compound heterozygous) pathogenic variants in the GATM gene. As confirmed: "biallelic pathogenic variants in GATM result in l-arginine:glycine amidinotransferase deficiency" (PMID: 36856349). There are no known environmental, infectious, or lifestyle causes. The disease follows strict Mendelian autosomal recessive inheritance.

Risk Factors

Genetic risk factors: - Carrier status for pathogenic GATM variants in both parents (obligate heterozygotes) - Consanguinity significantly increases risk; multiple reported families have consanguineous parents (PMID: 23770102) - No known susceptibility loci or modifier genes beyond GATM itself

Environmental risk factors: - Dietary creatine intake may modify phenotypic severity; vegetarian diets provide no dietary creatine, and individuals depend entirely on endogenous synthesis, which is absent in AGAT deficiency (PMID: 21387089) - Statin medications may exacerbate myopathy in carriers or affected individuals; the GATM gene has been associated with statin-induced myopathy in two human populations (PMID: 31853708)

Protective Factors

Genetic protective factors: - No specific protective alleles identified - Residual AGAT activity from hypomorphic variants may theoretically ameliorate phenotype, though no clear genotype-phenotype correlation exists (PMID: 27233232)

Environmental protective factors: - Dietary creatine from meat and fish provides approximately half of daily needs in omnivores - Early initiation of creatine supplementation is the most powerful protective intervention

Gene-Environment Interactions

• Statin exposure interacts with GATM genotype: simvastatin-induced motor impairment is exacerbated in AGAT-deficient mice (PMID: 31853708)
• Pregnancy increases creatine demand; an AGAT-deficient woman required dose escalation during pregnancy (PMID: 32883247)

3. Phenotypes

Core Clinical Features

As reported: "15 patients diagnosed between 16 months and 25 years of life had intellectual disability/developmental delay (IDD). 8 patients also had myopathy/proximal muscle weakness" (PMID: 26490222).

Laboratory Abnormalities

Quality of Life Impact

AGAT deficiency profoundly affects quality of life: intellectual disability ranges from mild to severe requiring special educational support; severe language impairment limits social interaction and independence; proximal weakness (Gowers sign positive) limits physical activities; and behavioral disturbances complicate caregiving and social integration. Most untreated or late-treated patients require lifelong supervision and support.

4. Genetic/Molecular Information

Causal Gene

The gene encodes L-arginine:glycine amidinotransferase, a mitochondrial enzyme catalyzing: L-arginine + glycine → L-ornithine + guanidinoacetate (GAA). As described: "There are two enzyme deficiencies, guanidinoacetate methyltransferase (GAMT), encoded by GAMT and arginine-glycine amidinotransferase (AGAT), encoded by GATM, which are involved in the synthesis of creatine" (PMID: 38452609).

Pathogenic Variants

The ClinGen CCDS VCEP has curated 45 variants in GATM (PMID: 38452609).

Selected reported pathogenic variants:

Variant characteristics: - Classification: Pathogenic and likely pathogenic per ACMG/AMP guidelines, curated by the CCDS VCEP - Variant types: Missense, nonsense, frameshift, splice-site variants have all been reported - Allele frequency: Extremely rare in population databases (gnomAD); most variants are private or near-private - Origin: All reported variants are germline - Functional consequence: Loss of function; seven missense variants showed 0% residual wild-type AGAT activity (PMID: 27233232)

Genotype-phenotype correlation: "Two patients with mild phenotype had a nonsense missense variant. Severe phenotype was present in patients with missense as well as truncating variants. There seems to be no phenotype and genotype correlation" (PMID: 27233232).

Modifier Genes

No modifier genes have been identified. Variation in phenotypic severity appears primarily influenced by age at treatment initiation.

Epigenetic Information

Transcriptomic analysis in AGAT-knockout mouse brains revealed homoarginine- and creatine-dependent gene regulation changes (PMID: 32182846). Creatine biosynthesis consumes approximately 40% of all S-adenosylmethionine (SAM)-derived methyl groups, suggesting that AGAT deficiency could indirectly affect the methylation landscape (PMID: 21387089).

Chromosomal Abnormalities

No large-scale chromosomal abnormalities are associated. A distinct GATM gain-of-function mechanism has been associated with autosomal dominant renal Fanconi syndrome (PMID: 29654216), but this is unrelated to AGAT deficiency.

5. Environmental Information

Environmental Factors

AGAT deficiency is purely genetic. No environmental toxins, radiation, or occupational exposures are implicated.

Lifestyle Factors

• Diet: Dietary creatine (primarily from meat and fish) provides an external source; vegetarian or vegan diets would theoretically exacerbate the phenotype
• Exercise: Physical activity increases creatine demand and may unmask or worsen myopathy
• Pregnancy: Substantially increases creatine demand; documented case required dose escalation (PMID: 32883247)

Infectious Agents

Not applicable.

6. Mechanism / Pathophysiology

Molecular Pathways

AGAT catalyzes the first and rate-limiting step of endogenous creatine biosynthesis:

L-Arginine + Glycine  ──AGAT──>  L-Ornithine + Guanidinoacetate (GAA)
                                    │
                              GAA + SAM  ──GAMT──>  Creatine + SAH
                                                        │
                                              Creatine + ATP  ──CK──>  Phosphocreatine + ADP

Key pathway identifiers: - KEGG: hsa00260 (Glycine, serine and threonine metabolism); hsa00330 (Arginine and proline metabolism) - Reactome: R-HSA-71288 (Creatine metabolism) - GO:0006601 (creatine biosynthetic process)

Cellular Processes and Functions of Creatine

Creatine and the creatine kinase/phosphocreatine (CK/PCr) system serve as: 1. Temporal energy buffer: PCr rapidly regenerates ATP in tissues with high and fluctuating energy demands 2. Spatial energy shuttle: Transports high-energy phosphate groups from mitochondria to sites of ATP consumption 3. Neuromodulator: "Creatine modulates GABAergic and glutamatergic cerebral pathways, presynaptic CRTR (SLC6A8) ensuring re-uptake of synaptic creatine" (PMID: 26542286) 4. Antioxidant: Direct antioxidant properties 5. Osmolyte: Contributes to cellular water retention in muscle

Causal Chain: From Genetic Defect to Clinical Manifestation

GATM biallelic mutations
 │
 ▼
Loss of AGAT enzyme activity (mitochondrial)
 │
 ├──> No GAA production ──> No substrate for GAMT ──> No endogenous creatine
 │
 ├──> Depletion of homoarginine (hArg) ──> Impaired NO signaling? ──> Cardiovascular effects
 │
 ▼
Systemic creatine depletion (dependent on dietary creatine only)
 │
 ├──> Brain: Cerebral creatine deficiency
 │         ├──> Impaired neuronal energy metabolism ──> Intellectual disability
 │         ├──> Disrupted GABAergic/glutamatergic signaling ──> Behavioral disturbances, epilepsy
 │         └──> Impaired brain development ──> Speech delay, corpus callosum dysmorphisms
 │
 ├──> Skeletal muscle: Muscle creatine depletion
 │         └──> Impaired energy metabolism ──> Proximal myopathy, hypotonia
 │
 └──> Heart: Cardiac creatine depletion
   └──> Altered calcium handling ──> Reduced contractility

Protein Dysfunction

AGAT (UniProt: P50440) is a mitochondrial matrix enzyme. Pathogenic variants result in protein truncation, misfolding, or catalytic site disruption. All characterized pathogenic missense variants show 0% residual activity (PMID: 27233232).

Metabolic Changes

• Creatine/phosphocreatine depletion: Primary metabolic abnormality; brain creatine undetectable on MRS
• GAA depletion: Absence of the creatine precursor (diagnostic hallmark)
• Homoarginine depletion: AGAT also synthesizes L-homoarginine; its deficiency may contribute to cardiovascular and cerebrovascular risk (PMID: 30370846)
• Reduced SAM consumption: GAMT-mediated creatine synthesis normally consumes ~40% of total SAM flux; in AGAT deficiency this demand is eliminated (PMID: 21387089)

Relevant CHEBI terms: CHEBI:16919 (creatine), CHEBI:17437 (guanidinoacetate), CHEBI:15354 (phosphocreatine), CHEBI:59560 (L-homoarginine), CHEBI:67079 (S-adenosylmethionine)

Cardiac Involvement (Mouse Model)

"Creatine-deficient mice, which lack arginine-glycine amidinotransferase (AGAT) to synthesize creatine and homoarginine, exhibit reduced cardiac contractility" (PMID: 33275525). The cardiac calcium handling defects are rescued by creatine supplementation.

Biochemical Abnormalities

The specific enzyme deficiency is in AGAT (EC 2.1.4.1, glycine amidinotransferase): - Substrate: L-arginine + glycine - Product: L-ornithine + guanidinoacetate - Localization: Mitochondrial matrix - Additional observations: Decreased respiratory chain complex activity in muscle tissue has been reported (PMID: 20682460), and tubular aggregates on electron microscopy

Molecular Profiling

Transcriptomics: Transcriptome analysis of AGAT-knockout mouse brains revealed gene regulation changes dependent on homoarginine and creatine status (PMID: 32182846). No transcriptomic, proteomic, metabolomic, or single-cell studies have been performed on human AGAT-deficiency patient samples due to extreme rarity.

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

Subcellular Level

Localization

• Cerebral cortex (UBERON:0000956): Reduced cortical thickness, especially parieto-occipital
• Corpus callosum (UBERON:0002336): Dysmorphisms in 3/4 affected family members
• Proximal muscles of lower limbs (UBERON:0004518): Primary myopathy site
• Kidney cortex (UBERON:0001225): Primary GAA synthesis organ
• Bilateral involvement typical for both brain and muscle manifestations

8. Temporal Development

Onset

• Typical age of onset: Infancy to early childhood (symptoms noticed between 6 months and 3 years)
• Age at diagnosis: Ranged from 16 months to 25 years in the largest cohort (PMID: 26490222)
• Onset pattern: Insidious; developmental milestones progressively delayed rather than lost
• Epilepsy onset: 4–6 years in reported cases (PMID: 40674085)

Progression

• Disease course: Chronic, progressive without treatment; stable to improving with creatine
• Duration: Lifelong condition

Critical Periods

The first months to years of life represent the critical therapeutic window. Two patients treated from ages 4 and 16 months achieved normal development by ages 10–11, while patients treated later showed limited cognitive improvement (PMID: 26490222). One patient treated from 16 months demonstrated "superior nonverbal and academic abilities, with average verbal skills" at 8-year follow-up (PMID: 22386973). This suggests irreversible damage from brain creatine depletion during neurodevelopmental critical periods.

9. Inheritance and Population

Epidemiology

• Prevalence: Ultra-rare; fewer than 50 patients identified worldwide; estimated <1 per 1,000,000
• Incidence: Unknown; too rare for reliable estimation
• Orphanet classification: Ultra-rare disease

Genetic Inheritance

• Inheritance pattern: Autosomal recessive (HP:0000007)
• Penetrance: Complete for biochemical phenotype; clinical severity variable
• Expressivity: Variable; influenced primarily by age at treatment initiation
• Genetic anticipation: Not applicable
• Germline mosaicism: Not reported but cannot be excluded
• Consanguinity role: Significant; multiple families consanguineous (PMID: 23770102)
• Carrier frequency: Unknown; estimated extremely low; functional characterization of rare GATM variants was performed to estimate frequency (PMID: 27233232)
• Founder effects: The c.446G>A, p.(Trp149Ter) variant appears recurrent in Italian families (PMID: 40674085)

Population Demographics

• Affected populations: 16 patients from 8 families of 8 different ethnic backgrounds, indicating no ethnic predilection (PMID: 26490222)
• Geographic distribution: Cases from Europe, Middle East, North Africa, North and South America; no clustering
• Sex ratio: Approximately equal (autosomal inheritance)
• Age distribution: Diagnosis ranges from infancy to adulthood; most in childhood

10. Diagnostics

Clinical Tests

Biochemical testing:

Methods include LC-MS/MS: "LC-MS/MS measurements of guanidinoacetic acid (GAA) and creatine in urine and plasma are an important screening test to identify the deficit" (PMID: 30858092).

Imaging: - Brain MRI: Corpus callosum dysmorphisms, reduced cortical thickness (PMID: 40323733) - Brain ¹H-MRS: Absent creatine peak at 3.0 ppm (key diagnostic finding) - Muscle electron microscopy: Tubular aggregates (PMID: 20682460)

Electrophysiology: - EMG: Myopathic pattern (PMID: 23770102) - EEG: Epileptiform activity in patients with seizures

Genetic Testing

• Recommended approach: Biochemical screening followed by GATM sequencing
• Gene panels: CCDS panels including GATM, GAMT, and SLC6A8 (PMID: 28055022)
• WES/WGS: Useful for unexplained ID workup
• ACMG technical standard: Guidelines standardize diagnostic procedures for all CCDS (PMID: 28055022)
• ClinGen VCEP guidelines: Disease-specific variant classification for GATM (PMID: 38452609)
• Enzyme activity assay: AGAT activity in lymphoblasts for functional confirmation (PMID: 22386973)

Differential Diagnosis

Screening

• Newborn screening: GATM deficiency is "a good candidate for newborn screening" given normal neurodevelopment in presymptomatically treated individuals (PMID: 27233232). Detection requires identifying LOW GAA, which is technically more challenging than detecting elevated GAA (used for GAMT-d screening). GAMT deficiency has been added to newborn screening in some US states (PMID: 34389248; PMID: 35120844).
• Cascade screening: Siblings and family members should be tested immediately when a proband is identified.
• Metabolic screening in autism/ID: Has identified CCDS cases; "An inborn error of metabolism was found in 13 (12.4%) patients. Five patients (4.8%) had cerebral creatine deficiency syndrome" (PMID: 36604934).

11. Outcome/Prognosis

Survival and Mortality

• Life expectancy: Likely near-normal with treatment; no deaths directly attributable to AGAT deficiency reported
• Mortality rate: Not established due to rarity
• Disease-specific mortality: None reported

Morbidity and Function

Complications

• Untreated: Progressive ID, severe language impairment, increasing disability
• Treatment-related: Weight gain, kidney stones (PMID: 28148286)
• Epilepsy: May develop even with supplementation (PMID: 40674085)
• Brain atrophy: May persist despite treatment (PMID: 40323733)

Prognostic Factors

The single most important prognostic factor is age at treatment initiation. As confirmed: "Early treatment prevents adverse developmental outcome, while patients diagnosed and treated at an older age showed partial but signif[icant improvement]" (PMID: 28148286).

12. Treatment

Pharmacotherapy: Creatine Monohydrate (Primary Treatment)

• MAXO term: MAXO:0001298 (dietary supplement therapy)
• Dose: 100–800 mg/kg/day orally, divided into multiple daily doses
• Mechanism: Replaces endogenous creatine; restores intracellular creatine and phosphocreatine pools

Treatment outcomes: "Treatment with creatine monohydrate (100-800 mg/kg/day) resulted in almost complete restoration of brain creatine levels and significant improvement of myopathy. The 2 patients treated since age 4 and 16 months had normal cognitive and behavioral development at age 10 and 11 years. Late treated patients had limited improvement of cognitive functions" (PMID: 26490222).

Long-term efficacy: "8 years post initiation of oral creatine supplementation, patient demonstrates superior nonverbal and academic abilities, with average verbal skills" (PMID: 22386973).

Side effects: Weight gain, kidney stones; generally safe and well tolerated (PMID: 28148286).

Potential Alternative: GAA Supplementation (Investigational)

GAA has been proposed as an alternative with potentially better brain bioavailability. However: "AGAT patients might benefit from oral GAA due to upgraded bioavailability and convenient utilization of the compound, while possible drawbacks (e.g. brain methylation issues, neurotoxicity, and hyperhomocysteinemia) should be accounted as well" (PMID: 28971744). This remains experimental.

Anticonvulsant Medications

For patients with epilepsy, carbamazepine and valproate/lacosamide combinations have been used (PMID: 40674085).

Supportive and Rehabilitative Care

• Speech therapy (MAXO:0000930): For language delay
• Physical therapy (MAXO:0000502): For myopathy and motor development
• Special education (MAXO:0000016): For intellectual disability
• Behavioral therapy: For behavioral disturbances
• Antiepileptic drugs (MAXO:0000759): If seizures present

Pregnancy Management

Pregnant women with AGAT deficiency require increased creatine doses with close monitoring (PMID: 32883247).

Advanced Therapeutics and Patient Advocacy

No gene therapy trials specific to AGAT deficiency are registered. The Association for Creatine Deficiencies (ACD) is actively advancing the field, supporting "advancements in disease diagnosis, investments in various therapeutic modalities, creation of a collaborative research community" (PMID: 40078706).

Treatment Algorithm

1. Confirm diagnosis biochemically and genetically
2. Initiate creatine monohydrate immediately (starting 200–400 mg/kg/day)
3. Monitor brain creatine by MRS at regular intervals
4. Adjust dose upward (to 800 mg/kg/day if needed) based on response
5. Monitor for side effects (weight, renal function, kidney stones)
6. Provide supportive therapies (speech, PT, OT) as needed
7. Screen siblings and treat presymptomatically if affected
8. Lifelong supplementation and monitoring

13. Prevention

Primary Prevention

• Genetic counseling (MAXO:0000079): For families with known GATM variants; 25% recurrence risk per pregnancy
• Preimplantation genetic diagnosis (PGD): Available for families with known mutations
• Prenatal testing: Molecular testing in at-risk pregnancies
• Consanguinity counseling: Important in populations with high consanguinity rates

Secondary Prevention (Early Detection)

• Newborn screening: AGAT deficiency is a strong NBS candidate due to treatability, but detection of LOW GAA presents technical challenges distinct from GAMT-d screening (elevated GAA)
• Cascade family screening: Critical; siblings of diagnosed patients should be immediately tested
• Metabolic screening in developmental delay cohorts: Children with unexplained DD, especially with myopathy, should be screened for CCDS

Tertiary Prevention

• Continuous lifelong creatine supplementation
• Regular monitoring: brain MRS, developmental assessments, renal function
• Dose adjustment during physiological stress (pregnancy, illness, growth spurts)
• Seizure surveillance and management

14. Other Species / Natural Disease

Taxonomy and Orthologous Genes

Natural Disease

No naturally occurring AGAT deficiency has been described in non-human species. The disorder has only been studied through engineered knockout mouse models. The creatine biosynthesis pathway (AGAT → GAMT) is evolutionarily conserved across vertebrates, indicating its fundamental importance in energy metabolism.

15. Model Organisms

AGAT-Knockout Mouse (Primary Model)

Key phenotypic findings:

1. Cardiac: "Creatine-deficient mice, which lack arginine-glycine amidinotransferase (AGAT) to synthesize creatine and homoarginine, exhibit reduced cardiac contractility" — reduced L-type calcium channel current, slower calcium transient decay; rescued by creatine (PMID: 33275525)

2. Muscular: "Simvastatin-induced motor impairment was exacerbated in AGAT-deficient mice compared with AGAT-overexpressing GAMT" — GATM associated with statin myopathy in humans (PMID: 31853708)

3. Cerebral: Homoarginine- and creatine-dependent gene regulation changes in brain (PMID: 32182846)

Model limitations: - Behavioral phenotyping shows only mild and limited alterations compared to the significant human cognitive impairment - Brain development timelines differ between species - Speech and language assessment is not possible in mice

GAMT-Knockout Mouse (Related Model)

Shares creatine depletion phenotype but additionally accumulates GAA (potentially neurotoxic), providing a complementary model for studying creatine deficiency vs. GAA toxicity effects (PMID: 34440375).

Mechanistic Model / Interpretation

The pathophysiology of AGAT deficiency can be understood as a biosynthetic energy deficiency disorder with tissue-specific vulnerability:

       ┌─────────────────────────┐
       │   GATM Gene Mutations    │
       │   (Biallelic, LOF)       │
       └─────────┬───────────────┘
                 │
       ┌─────────▼───────────────┐
       │ AGAT Enzyme Absent       │
       │ (Mitochondrial Matrix)   │
       └─────────┬───────────────┘
                 │
      ┌──────────────────┼──────────────────┐
      │                  │                   │
    ┌─────────▼──────┐  ┌───────▼───────┐  ┌───────▼────────┐
    │ No GAA Produced │  │ No Homoarginine│  │ Reduced SAM    │
    │                 │  │ (hArg)         │  │ Consumption    │
    └─────────┬──────┘  └───────┬───────┘  └───────┬────────┘
      │                 │                   │
    ┌─────────▼──────┐  ┌───────▼───────┐  ┌───────▼────────┐
    │ No Endogenous  │  │ Cardiovascular │  │ Methylation    │
    │ Creatine       │  │ Risk?          │  │ Balance Shift  │
    └─────────┬──────┘  └───────────────┘  └────────────────┘
      │
    ┌─────────▼───────────────────────────────────┐
    │ SYSTEMIC CREATINE/PHOSPHOCREATINE DEPLETION │
    └──────┬──────────────┬──────────────┬────────┘
   │              │              │
  ┌────────▼─────┐ ┌─────▼─────┐ ┌──────▼──────┐
  │   BRAIN      │ │  MUSCLE   │ │   HEART     │
  │ - ID         │ │ - Myopathy│ │ - Altered   │
  │ - Speech ↓   │ │ - Hypotonia│ │   Ca²⁺     │
  │ - Behavior   │ │ - Weakness│ │   handling  │
  │ - Epilepsy   │ │           │ │             │
  │ - Atrophy    │ │           │ │             │
  └──────────────┘ └───────────┘ └─────────────┘

The brain is most severely affected because: (1) it has the highest energy demand per unit mass; (2) the blood-brain barrier has limited permeability for peripheral creatine ("SLC6A8 is expressed by microcapillary endothelial cells at the blood-brain barrier, but is absent from surrounding astrocytes" — PMID: 26861125); and (3) intracerebral creatine synthesis is disrupted. The critical dependence on the neurodevelopmental time window explains why early treatment prevents damage while late treatment has limited cognitive benefit.

Evidence Base

Key Literature

Ontology Term Summary

Disease Ontology

• MONDO: MONDO:0012999
• OMIM: 612718
• Orphanet: ORPHA:35704

HPO (Human Phenotype Ontology)

• HP:0001249 (Intellectual disability) | HP:0001263 (Global developmental delay)
• HP:0000750 (Delayed speech and language development) | HP:0002474 (Expressive language delay)
• HP:0003198 (Myopathy) | HP:0003701 (Proximal muscle weakness)
• HP:0001252 (Muscular hypotonia) | HP:0000729 (Autistic behavior)
• HP:0000708 (Atypical behavior) | HP:0001250 (Seizures) | HP:0007359 (Focal-onset seizure)
• HP:0001508 (Failure to thrive) | HP:0002120 (Cerebral cortical atrophy)
• HP:0001273 (Abnormal corpus callosum morphology) | HP:0000007 (Autosomal recessive inheritance)

GO (Gene Ontology)

• GO:0006601 (creatine biosynthetic process) | GO:0006600 (creatine metabolic process)
• GO:0015068 (glycine amidinotransferase activity) | GO:0016740 (transferase activity)
• GO:0005759 (mitochondrial matrix) | GO:0005739 (mitochondrion) | GO:0005737 (cytoplasm)

CL (Cell Ontology)

• CL:0000540 (neuron) | CL:0000127 (astrocyte) | CL:0000128 (oligodendrocyte)
• CL:0000187 (muscle cell) | CL:0000746 (cardiac muscle cell) | CL:0002306 (renal tubular epithelial cell)

UBERON (Anatomical Ontology)

• UBERON:0000955 (brain) | UBERON:0000956 (cerebral cortex) | UBERON:0002336 (corpus callosum)
• UBERON:0001134 (skeletal muscle tissue) | UBERON:0000948 (heart) | UBERON:0002113 (kidney)

CHEBI (Chemical Entities)

• CHEBI:16919 (creatine) | CHEBI:17437 (guanidinoacetate) | CHEBI:15354 (phosphocreatine)
• CHEBI:59560 (L-homoarginine) | CHEBI:67079 (S-adenosylmethionine) | CHEBI:16737 (creatinine)

MAXO (Medical Action Ontology)

• MAXO:0001298 (dietary supplement therapy) | MAXO:0000079 (genetic counseling)
• MAXO:0000930 (speech-language therapy) | MAXO:0000502 (physical therapy)
• MAXO:0000016 (education) | MAXO:0000759 (antiepileptic drug therapy)

Limitations and Knowledge Gaps

1. Extreme rarity: Fewer than 50 patients identified worldwide; all data from small case series and case reports. Robust epidemiological data, natural history studies, and clinical trials are not feasible.

2. Ascertainment bias: The nonspecific early phenotype (developmental delay, speech delay) means AGAT deficiency is almost certainly underdiagnosed. Many patients may carry diagnoses of "idiopathic intellectual disability."

3. No genotype-phenotype correlation: Despite functional characterization of multiple variants, outcome appears determined primarily by age at treatment rather than mutation type.

4. Limited long-term data: Longest follow-up is 15 years. Lifelong trajectory including potential late-onset complications (cardiovascular, renal) remains unknown.

5. Cardiac phenotype uncharacterized in humans: The mouse model clearly shows cardiac dysfunction, but systematic cardiac evaluation in human patients has not been reported.

6. Persistent brain changes: Reduced cortical thickness and corpus callosum dysmorphisms persist despite supplementation, suggesting some structural changes are irreversible or independent of creatine status.

7. Homoarginine deficiency: Clinical significance of concurrent homoarginine depletion in AGAT-deficient patients is poorly understood.

8. Newborn screening not implemented: Unlike GAMT deficiency (added to US RUSP), AGAT deficiency detection requires identifying LOW GAA, presenting distinct technical challenges.

9. No molecular profiling in humans: No transcriptomic, proteomic, or metabolomic studies on patient samples exist.

Proposed Follow-up Studies and Actions

1. Newborn screening for AGAT deficiency: Develop and validate dried blood spot assays optimized to detect low GAA, in parallel with existing GAMT-d programs.

2. International patient registry: Establish a centralized, prospective registry for systematic natural history data and outcome collection.

3. Cardiac evaluation protocol: Conduct echocardiographic and cardiac MRI evaluation of all known AGAT-deficient patients, based on compelling mouse model evidence.

4. Homoarginine supplementation study: Investigate whether L-homoarginine supplementation provides additional cardiovascular or neurological benefit.

5. Longitudinal brain imaging: Perform volumetric MRI and diffusion tensor imaging to characterize structural changes and their relationship to treatment timing.

6. Multi-omics profiling: Conduct metabolomics and transcriptomics on patient-derived samples to identify biomarkers and secondary metabolic disturbances.

7. Statin pharmacogenomics: Consider GATM genotyping in patients experiencing statin adverse effects, given the human genetic association and mouse model data.

8. Gene therapy feasibility: Explore AAV-mediated GATM gene replacement in the mouse model, given the monogenic nature and clear biochemical endpoints.

9. Metabolic screening in DD/ID/ASD cohorts: Implement routine creatine metabolism screening in all children with unexplained developmental delay, especially when consanguinity is present.

10. GAA supplementation pilot: Design a carefully monitored study of oral GAA as creatine adjunct, with close monitoring of methylation status and homocysteine.

Report compiled from systematic review of 38 publications and comprehensive database searches. All citations verified against PubMed abstracts. Last updated: May 2026.